Anticancer Activity of Fascaplysin against Lung Cancer Cell and Small Cell Lung Cancer Circulating Tumor Cell Lines
Lung cancer is a leading cause of tumor-associated mortality. Fascaplysin, a bis-indole of a marine sponge, exhibit broad anticancer activity as specific CDK4 inhibitor among several other mechanisms, and is investigated as a drug to overcome chemoresistance after the failure of targeted agents or i...
Saved in:
Published in | Marine drugs Vol. 16; no. 10; p. 383 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
MDPI AG
14.10.2018
MDPI |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Lung cancer is a leading cause of tumor-associated mortality. Fascaplysin, a bis-indole of a marine sponge, exhibit broad anticancer activity as specific CDK4 inhibitor among several other mechanisms, and is investigated as a drug to overcome chemoresistance after the failure of targeted agents or immunotherapy. The cytotoxic activity of fascaplysin was studied using lung cancer cell lines, primary Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) cells, as well as SCLC circulating tumor cell lines (CTCs). This compound exhibited high activity against SCLC cell lines (mean IC
0.89 µM), as well as SCLC CTCs as single cells and in the form of tumorospheres (mean IC
0.57 µM). NSCLC lines showed a mean IC
of 1.15 µM for fascaplysin. Analysis of signal transduction mediators point to an ATM-triggered signaling cascade provoked by drug-induced DNA damage. Fascaplysin reveals at least an additive cytotoxic effect with cisplatin, which is the mainstay of lung cancer chemotherapy. In conclusion, fascaplysin shows high activity against lung cancer cell lines and spheroids of SCLC CTCs which are linked to the dismal prognosis of this tumor type. Derivatives of fascaplysin may constitute valuable new agents for the treatment of lung cancer. |
---|---|
AbstractList | Lung cancer is a leading cause of tumor-associated mortality. Fascaplysin, a bis-indole of a marine sponge, exhibit broad anticancer activity as specific CDK4 inhibitor among several other mechanisms, and is investigated as a drug to overcome chemoresistance after the failure of targeted agents or immunotherapy. The cytotoxic activity of fascaplysin was studied using lung cancer cell lines, primary Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) cells, as well as SCLC circulating tumor cell lines (CTCs). This compound exhibited high activity against SCLC cell lines (mean IC
50
0.89 µM), as well as SCLC CTCs as single cells and in the form of tumorospheres (mean IC
50
0.57 µM). NSCLC lines showed a mean IC
50
of 1.15 µM for fascaplysin. Analysis of signal transduction mediators point to an ATM-triggered signaling cascade provoked by drug-induced DNA damage. Fascaplysin reveals at least an additive cytotoxic effect with cisplatin, which is the mainstay of lung cancer chemotherapy. In conclusion, fascaplysin shows high activity against lung cancer cell lines and spheroids of SCLC CTCs which are linked to the dismal prognosis of this tumor type. Derivatives of fascaplysin may constitute valuable new agents for the treatment of lung cancer. Lung cancer is a leading cause of tumor-associated mortality. Fascaplysin, a bis-indole of a marine sponge, exhibit broad anticancer activity as specific CDK4 inhibitor among several other mechanisms, and is investigated as a drug to overcome chemoresistance after the failure of targeted agents or immunotherapy. The cytotoxic activity of fascaplysin was studied using lung cancer cell lines, primary Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) cells, as well as SCLC circulating tumor cell lines (CTCs). This compound exhibited high activity against SCLC cell lines (mean IC50 0.89 µM), as well as SCLC CTCs as single cells and in the form of tumorospheres (mean IC50 0.57 µM). NSCLC lines showed a mean IC50 of 1.15 µM for fascaplysin. Analysis of signal transduction mediators point to an ATM-triggered signaling cascade provoked by drug-induced DNA damage. Fascaplysin reveals at least an additive cytotoxic effect with cisplatin, which is the mainstay of lung cancer chemotherapy. In conclusion, fascaplysin shows high activity against lung cancer cell lines and spheroids of SCLC CTCs which are linked to the dismal prognosis of this tumor type. Derivatives of fascaplysin may constitute valuable new agents for the treatment of lung cancer. Lung cancer is a leading cause of tumor-associated mortality. Fascaplysin, a bis-indole of a marine sponge, exhibit broad anticancer activity as specific CDK4 inhibitor among several other mechanisms, and is investigated as a drug to overcome chemoresistance after the failure of targeted agents or immunotherapy. The cytotoxic activity of fascaplysin was studied using lung cancer cell lines, primary Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) cells, as well as SCLC circulating tumor cell lines (CTCs). This compound exhibited high activity against SCLC cell lines (mean IC 0.89 µM), as well as SCLC CTCs as single cells and in the form of tumorospheres (mean IC 0.57 µM). NSCLC lines showed a mean IC of 1.15 µM for fascaplysin. Analysis of signal transduction mediators point to an ATM-triggered signaling cascade provoked by drug-induced DNA damage. Fascaplysin reveals at least an additive cytotoxic effect with cisplatin, which is the mainstay of lung cancer chemotherapy. In conclusion, fascaplysin shows high activity against lung cancer cell lines and spheroids of SCLC CTCs which are linked to the dismal prognosis of this tumor type. Derivatives of fascaplysin may constitute valuable new agents for the treatment of lung cancer. |
Author | Hochmair, Maximilian Plangger, Adelina Hamilton, Gerhard Rath, Barbara |
AuthorAffiliation | Department of Surgery, Medical University of Vienna, A-1090 Vienna, Austria; barbara.rath@gmx.eu (B.R.); maximilian.hochmair@wienkav.at (M.H.); a01331326@unet.univie.ac.at (A.P.) |
AuthorAffiliation_xml | – name: Department of Surgery, Medical University of Vienna, A-1090 Vienna, Austria; barbara.rath@gmx.eu (B.R.); maximilian.hochmair@wienkav.at (M.H.); a01331326@unet.univie.ac.at (A.P.) |
Author_xml | – sequence: 1 givenname: Barbara surname: Rath fullname: Rath, Barbara email: barbara.rath@gmx.eu organization: Department of Surgery, Medical University of Vienna, A-1090 Vienna, Austria. barbara.rath@gmx.eu – sequence: 2 givenname: Maximilian surname: Hochmair fullname: Hochmair, Maximilian email: maximilian.hochmair@wienkav.at organization: Department of Surgery, Medical University of Vienna, A-1090 Vienna, Austria. maximilian.hochmair@wienkav.at – sequence: 3 givenname: Adelina surname: Plangger fullname: Plangger, Adelina email: a01331326@unet.univie.ac.at organization: Department of Surgery, Medical University of Vienna, A-1090 Vienna, Austria. a01331326@unet.univie.ac.at – sequence: 4 givenname: Gerhard surname: Hamilton fullname: Hamilton, Gerhard email: gerhard.hamilton@meduniwien.ac.at organization: Department of Surgery, Medical University of Vienna, A-1090 Vienna, Austria. gerhard.hamilton@meduniwien.ac.at |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30322180$$D View this record in MEDLINE/PubMed |
BookMark | eNpdkk1vEzEQhi1URD_gwg9AK3FBSAGPvWvvXpCiiEKlSBwoZ2vWH8HRrh3s3Ur593WbUBpOHr_z-NXMeC7JWYjBEvIW6CfOO_p5NCCAUt7yF-QChKCLIsuzZ_E5ucx5W5Cm7epX5JxTzhi09ILkZZi8xqBtqpZ68nd-2lfRVdeYNe6Gffahwg36kKdqPYdNtTqwKzsMFQZT_RyxRI_Xk7xPeh5w8kW6ncd4fLH2webX5KXDIds3x_OK_Lr-erv6vlj_-HazWq4XupZsWjjOaW-h6ylD2aCT0qEVBlln6sbwtmXW9VoLwTow3AJ3wtFOQ4OUYg2OX5Gbg6-JuFW75EdMexXRq0chpo3CVLofrNISpOCmdqxhdW9NT01fA0Br6tZgZ4rXl4PXbu5Ha7QNU8LhxPQ0E_xvtYl3SjDgULNi8OFokOKf2eZJjT7rMhMMNs5ZMWBUNtDIrqDv_0O3cU6hjOqBEm1bPr0p1McDpVPMOVn3VAxQ9bAX6t9eFPjd8_Kf0L-LwO8Bx4C06w |
CitedBy_id | crossref_primary_10_1002_cbdv_202300883 crossref_primary_10_3390_md22030101 crossref_primary_10_3390_md17010031 crossref_primary_10_12714_egejfas_38_1_12 crossref_primary_10_1016_j_yexcr_2023_113904 crossref_primary_10_1080_10408398_2022_2108367 crossref_primary_10_3390_antibiotics9110813 crossref_primary_10_1007_s13205_021_02812_w crossref_primary_10_3390_molecules27238367 crossref_primary_10_1002_aoc_6640 crossref_primary_10_3390_molecules29050933 crossref_primary_10_1016_j_bcp_2021_114589 crossref_primary_10_1016_j_biopha_2019_108866 crossref_primary_10_1016_j_cbi_2024_110940 crossref_primary_10_3390_molecules26030663 crossref_primary_10_3390_md21040226 crossref_primary_10_3390_md18120643 crossref_primary_10_3390_md17090496 crossref_primary_10_3389_fchem_2021_614154 crossref_primary_10_3390_ph14030282 crossref_primary_10_1007_s10637_021_01181_8 crossref_primary_10_3390_foundations1010002 crossref_primary_10_1016_j_jpba_2019_04_012 crossref_primary_10_3390_biomedicines9080886 crossref_primary_10_3389_fphar_2020_572574 crossref_primary_10_1002_slct_202201441 crossref_primary_10_1002_jhet_4438 crossref_primary_10_1016_j_rechem_2021_100183 crossref_primary_10_1016_j_ejmech_2024_116347 crossref_primary_10_3390_md20030185 crossref_primary_10_1016_j_ejmech_2022_114748 crossref_primary_10_3390_md21080424 |
Cites_doi | 10.1021/np049935+ 10.1016/j.clbc.2014.10.001 10.1016/j.ctrv.2016.01.003 10.2174/138955710791384072 10.1358/dot.2014.50.07.2185913 10.1007/s10517-018-4055-4 10.1038/nature25183 10.2174/138955712800626719 10.3322/caac.21492 10.2174/1381612033454126 10.1002/jcb.25053 10.4236/jct.2013.48A008 10.1021/jm5014743 10.1016/j.biopha.2009.04.046 10.1038/cddis.2015.96 10.1038/s41598-017-05562-z 10.3390/molecules19022077 10.1055/s-0036-1592116 10.1093/jnci/93.6.436 10.1158/0008-5472.CAN-09-1947 10.1074/jbc.M113.464057 10.3816/CCC.2010.n.012 10.1093/jmcb/mju045 10.3390/md12031377 10.1053/hupa.2003.8 10.1371/journal.pone.0042612 10.1016/j.cbi.2017.07.017 10.3390/ijms18102074 10.1016/S0040-4039(03)00671-3 10.1006/bbrc.2000.3349 10.1016/j.molcel.2010.09.019 10.2174/187152008786847738 10.3390/molecules23010042 10.1016/j.coph.2013.03.012 10.5306/wjco.v5.i4.576 10.1016/j.ejps.2011.04.018 10.1016/S0968-0896(00)00313-8 10.1016/j.pharmthera.2017.02.008 10.1074/jbc.274.28.19559 10.1016/S1476-5586(03)80025-8 10.1128/MCB.00349-13 10.1016/j.ygyno.2005.11.017 10.1038/sj.bjc.6603167 10.1021/jo00249a025 10.3390/md15100310 |
ContentType | Journal Article |
Copyright | 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2018 by the authors. 2018 |
Copyright_xml | – notice: 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2018 by the authors. 2018 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7T7 7TN 7X7 7XB 88E 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI BKSAR C1K CCPQU DWQXO F1W FR3 FYUFA GHDGH GNUQQ H95 H99 HCIFZ K9. L.F L.G LK8 M0S M1P M7P P64 PCBAR PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.3390/md16100383 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Industrial and Applied Microbiology Abstracts (Microbiology A) Oceanic Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central ProQuest Natural Science Collection Earth, Atmospheric & Aquatic Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea ASFA: Aquatic Sciences and Fisheries Abstracts Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources ASFA: Marine Biotechnology Abstracts SciTech Premium Collection (Proquest) (PQ_SDU_P3) ProQuest Health & Medical Complete (Alumni) Aquatic Science & Fisheries Abstracts (ASFA) Marine Biotechnology Abstracts Aquatic Science & Fisheries Abstracts (ASFA) Professional ProQuest Biological Science Collection Health & Medical Collection (Alumni Edition) Medical Database Biological Science Database Biotechnology and BioEngineering Abstracts Earth, Atmospheric & Aquatic Science Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database Aquatic Science & Fisheries Abstracts (ASFA) Professional ProQuest Central Student Technology Research Database ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central Earth, Atmospheric & Aquatic Science Collection Health Research Premium Collection Oceanic Abstracts Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection Aquatic Science & Fisheries Abstracts (ASFA) Marine Biotechnology Abstracts Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Earth, Atmospheric & Aquatic Science Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ASFA: Aquatic Sciences and Fisheries Abstracts Engineering Research Database ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1660-3397 |
ExternalDocumentID | oai_doaj_org_article_c71763d4f2524bedb0db41118d48da9d 10_3390_md16100383 30322180 |
Genre | Journal Article |
GroupedDBID | --- 29M 2WC 3V. 53G 5GY 5VS 7X7 88E 8CJ 8FE 8FH 8FI 8FJ AADQD AAHBH ABUWG ACGFO ACIHN ACPRK ADBBV ADRAZ AEAQA AENEX AFKRA AFRAH AFZYC AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BBNVY BCNDV BENPR BHPHI BKSAR BPHCQ BVXVI CCPQU CGR CS3 CUY CVF D1J DIK DU5 E3Z EBD ECM EDH EIF F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IPNFZ KQ8 LK5 LK8 M1P M48 M7P M7R MK0 MODMG M~E NPM O5R O5S OK1 P2P PCBAR PGMZT PIMPY PQQKQ PROAC PSQYO RIG RNS RPM TR2 UKHRP XSB AAYXX CITATION 7T7 7TN 7XB 8FD 8FK AZQEC C1K DWQXO F1W FR3 GNUQQ H95 H99 K9. L.F L.G P64 PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c472t-f330be19b02a75af77fae6da29d45d3882efbcc66291d3e13f6f09c15a00a41f3 |
IEDL.DBID | RPM |
ISSN | 1660-3397 |
IngestDate | Thu Sep 05 15:41:12 EDT 2024 Tue Sep 17 21:19:01 EDT 2024 Fri Aug 16 01:13:23 EDT 2024 Thu Oct 10 21:07:04 EDT 2024 Fri Aug 23 00:34:25 EDT 2024 Tue Aug 27 13:48:45 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Keywords | lung cancer fascaplysin circulating tumor cells cisplatin signal transduction cytotoxicity |
Language | English |
License | Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c472t-f330be19b02a75af77fae6da29d45d3882efbcc66291d3e13f6f09c15a00a41f3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213142/ |
PMID | 30322180 |
PQID | 2126883905 |
PQPubID | 2032365 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_c71763d4f2524bedb0db41118d48da9d pubmedcentral_primary_oai_pubmedcentral_nih_gov_6213142 proquest_miscellaneous_2120751579 proquest_journals_2126883905 crossref_primary_10_3390_md16100383 pubmed_primary_30322180 |
PublicationCentury | 2000 |
PublicationDate | 2018-10-14 |
PublicationDateYYYYMMDD | 2018-10-14 |
PublicationDate_xml | – month: 10 year: 2018 text: 2018-10-14 day: 14 |
PublicationDecade | 2010 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland – name: Basel |
PublicationTitle | Marine drugs |
PublicationTitleAlternate | Mar Drugs |
PublicationYear | 2018 |
Publisher | MDPI AG MDPI |
Publisher_xml | – name: MDPI AG – name: MDPI |
References | ref13 ref35 ref12 ref34 ref15 ref37 ref14 ref36 ref31 ref30 ref11 ref33 ref10 ref32 ref1 ref17 ref39 ref16 ref38 ref19 ref18 Shapiro (ref29) 1995; 55 ref24 ref46 ref23 ref45 ref26 ref25 ref20 ref42 ref41 ref22 ref44 ref21 ref43 ref28 ref27 ref8 ref7 ref9 ref4 ref3 ref6 ref5 ref40 Herbst (ref2) 2018; 553 |
References_xml | – ident: ref9 doi: 10.1021/np049935+ – ident: ref27 doi: 10.1016/j.clbc.2014.10.001 – ident: ref6 doi: 10.1016/j.ctrv.2016.01.003 – ident: ref26 doi: 10.2174/138955710791384072 – ident: ref4 doi: 10.1358/dot.2014.50.07.2185913 – ident: ref46 doi: 10.1007/s10517-018-4055-4 – volume: 553 start-page: 446 year: 2018 ident: ref2 article-title: The biology and management of non-small cell lung cancer publication-title: Nature doi: 10.1038/nature25183 contributor: fullname: Herbst – ident: ref11 doi: 10.2174/138955712800626719 – ident: ref1 doi: 10.3322/caac.21492 – ident: ref36 doi: 10.2174/1381612033454126 – ident: ref17 doi: 10.1002/jcb.25053 – ident: ref21 doi: 10.4236/jct.2013.48A008 – ident: ref16 doi: 10.1021/jm5014743 – ident: ref19 doi: 10.1016/j.biopha.2009.04.046 – volume: 55 start-page: 505 year: 1995 ident: ref29 article-title: Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines publication-title: Cancer Res. contributor: fullname: Shapiro – ident: ref45 doi: 10.1038/cddis.2015.96 – ident: ref7 doi: 10.1038/s41598-017-05562-z – ident: ref22 doi: 10.3390/molecules19022077 – ident: ref3 doi: 10.1055/s-0036-1592116 – ident: ref13 doi: 10.1093/jnci/93.6.436 – ident: ref23 doi: 10.1158/0008-5472.CAN-09-1947 – ident: ref33 doi: 10.1074/jbc.M113.464057 – ident: ref37 doi: 10.3816/CCC.2010.n.012 – ident: ref32 doi: 10.1093/jmcb/mju045 – ident: ref20 doi: 10.3390/md12031377 – ident: ref28 doi: 10.1053/hupa.2003.8 – ident: ref14 doi: 10.1371/journal.pone.0042612 – ident: ref42 doi: 10.1016/j.cbi.2017.07.017 – ident: ref41 doi: 10.3390/ijms18102074 – ident: ref10 doi: 10.1016/S0040-4039(03)00671-3 – ident: ref12 doi: 10.1006/bbrc.2000.3349 – ident: ref31 doi: 10.1016/j.molcel.2010.09.019 – ident: ref40 doi: 10.2174/187152008786847738 – ident: ref43 doi: 10.3390/molecules23010042 – ident: ref24 doi: 10.1016/j.coph.2013.03.012 – ident: ref5 doi: 10.5306/wjco.v5.i4.576 – ident: ref18 doi: 10.1016/j.ejps.2011.04.018 – ident: ref15 doi: 10.1016/S0968-0896(00)00313-8 – ident: ref25 doi: 10.1016/j.pharmthera.2017.02.008 – ident: ref34 doi: 10.1074/jbc.274.28.19559 – ident: ref38 doi: 10.1016/S1476-5586(03)80025-8 – ident: ref39 doi: 10.1128/MCB.00349-13 – ident: ref35 doi: 10.1016/j.ygyno.2005.11.017 – ident: ref30 doi: 10.1038/sj.bjc.6603167 – ident: ref8 doi: 10.1021/jo00249a025 – ident: ref44 doi: 10.3390/md15100310 |
SSID | ssj0035894 |
Score | 2.412911 |
Snippet | Lung cancer is a leading cause of tumor-associated mortality. Fascaplysin, a bis-indole of a marine sponge, exhibit broad anticancer activity as specific CDK4... |
SourceID | doaj pubmedcentral proquest crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 383 |
SubjectTerms | A549 Cells Additives Angiogenesis Anticancer properties Antineoplastic Agents - pharmacology Antitumor activity Apoptosis Biotechnology Breast cancer Cancer Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Cell cycle Cell Line, Tumor Cell lines Cells Chemoresistance Chemotherapy circulating tumor cells Cisplatin Cisplatin - pharmacology Colorectal cancer Cyclin-dependent kinase 4 Cyclin-dependent kinases Cytotoxicity Deoxyribonucleic acid DNA DNA damage Drugs fascaplysin Humans Immunotherapy Indoles Indoles - pharmacology Kinases Lines Lung cancer Lung Neoplasms - drug therapy Lungs Marine invertebrates Medical prognosis Neoplasms Neoplastic Cells, Circulating - drug effects Non-small cell lung carcinoma Ovarian cancer Phosphorylation Proteins Signal transduction Signal Transduction - drug effects Small cell lung carcinoma Spheroids Tumor cell lines Tumors Vascular endothelial growth factor |
SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT1wQbwIFGYF6aoTfiY_LilWFCqrEVuot8hNWarPVPg7994zt7G6DkLhwS2xHsj0znm9s5xuEPkrNiG5FqFUbfS1iILVupa2J40H7pnE-pP2Ob9_V2aX4eiWv7qX6SnfCCj1wmbhPDuINxb2ITDJhg7fEWwEG2nrReqN9Xn2p3AVTZQ3mstWikJFyCOohuAdgkw7B-Mj9ZJb-v0HLP29I3nM5s8fo0YAV8aT08Ql6EPqn6OSikE3fneL54d-p9Sk-wRcHGuq7Z2g96dM-NQh1hSeuJInAy4hnZu3MbWIi6bH5aRaAD_E5mDyelrbTcH2NTe_xjxsDT_l1VL9YuZzzC4rm25vl8MV5uj__HF3OvsynZ_WQYqF2omGbOnJObKDaEmYaaWLTRBOUN0x7IT0H-B2idU4ppqnngfKoItGOSkOIETTyF-ioX_bhFcIyCqGZZ0RpLZyxGgCxp8K1VlEHsKxCH3Yz390WJo0OIpAkn-4gnwp9TkLZt0js17kAdKIbdKL7l05U6Hgn0m4wyXUHPlq1AAeJrND7fTUYUzohMX1YbnMbgFBUNrpCL4sG7HsCvp4BHiIVaka6MerquKZf_MqE3YpRTgV7_T_G9gY9BMyWKXmpOEZHm9U2vAVctLHvsgn8BpgaDhg priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Jb9NAFB5Be-GC2DEUNAjUUy1mt-eE0qhRhUoVQSr1Zs1aIrV2iJND_z1vbCchCHGzZ5FGfst88974ewh9kpoRXYqQqzL6XMRAcl1KmxPHg_ZF4XxI8Y5vl-r8Sny9ltdDwK0drlVufGLnqH3jUoz8M7hYVcJuTuSXxa88VY1K2dWhhMZDdMioSGnaw9Ozy-n3jS_mstSiJyXlMBUO-QBwUjKM721DHVv_vyDm3zcl_9h6Jk_Q4wEz4lEv5KfoQaifoeNpTzp9f4Jnu3-o2hN8jKc7Our756gd1SleDcJd4pHri0XgJuKJaZ1ZJEaSGpsbMweciC_A9PG4HzsOt7fY1B7_uDPw1L3u9c-Xrqv9BU2z9V0zzLhI9-hfoKvJ2Wx8ng-lFnInCrbKI-fEBqotYaaQJhZFNEF5w7QX0nOA4SFa55RimnoeKI8qEu2oNIQYQSN_iQ7qpg6vEZZRCM08I0pr4YzVAIw9Fa60ijqAZxn6uPny1aJn1KjgJJLkU-3kk6HTJJTtiMSC3TU0y5tqMKrKwVlUcS8ik0zY4C3xVoDzLr0ovdE-Q0cbkVaDabbVTpEy9GHbDUaVMiWmDs26GwNQispCZ-hVrwHblcCezwAXkQwVe7qxt9T9nnr-syPuVoxyKtib_y_rLXoEqKwj3aXiCB2sluvwDpDPyr4f1Ps3i84Glg priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1La9wwEBZpeuml9F23aVFpySkuets6lLJduoSSlEB3ITcj65EsbOzUuwvdf9-R7d2tQw692XqA0Iw032ikbxD6JDUjOhc-VXlwqQiepDqXZUos99plmXU-nnec_1SnM_HjUl4eoG3-zn4Cl_e6djGf1KxZfP7ze_MVFvyX6HGCyw6uO8CWGOLiD9BDJriImn4udtEELvM2ISJVCvYcMMAdTemdvgPD1PL33wc6796d_McYTZ6gxz2KxKNO7E_Rga-eoeOLjoZ6c4Kn-1dVyxN8jC_2BNWb52g5quIJNoi7wSPbpY_AdcATs7TmNnKUVNhcmTkgR3wGmwEed23HfrHApnL4142Br_Z3UD9vbJsNDIqm65u673EWb9a_QLPJ9-n4NO2TL6RWZGyVBs5J6akuCTOZNCHLgvHKGaadkI4DMPehtFYppqnjnvKgAtGWSkOIETTwl-iwqiv_GmEZhNDMMaK0FtaUGqCyo8LmpaIWAFuCPm5nvrjtODYK8E2ifIq9fBL0LQpl1yLyYrcFdXNV9MussOCdKu5EYJKJ0ruSuFLAdp47kTujXYKOtiIttrpWgPVWOQBFIhP0YVcNyyzGTkzl63XbBsAVlZlO0KtOA3YjARTAACmRBGUD3RgMdVhTza9bKm_FKKeCvfmvGXiLHgFca9l4qThCh6tm7d8BJFqV71t9_wty4wqj priority: 102 providerName: Scholars Portal |
Title | Anticancer Activity of Fascaplysin against Lung Cancer Cell and Small Cell Lung Cancer Circulating Tumor Cell Lines |
URI | https://www.ncbi.nlm.nih.gov/pubmed/30322180 https://www.proquest.com/docview/2126883905 https://search.proquest.com/docview/2120751579 https://pubmed.ncbi.nlm.nih.gov/PMC6213142 https://doaj.org/article/c71763d4f2524bedb0db41118d48da9d |
Volume | 16 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswECWS9NJL0b1qU4NFi5yimOIiiUfHiBEUcWC0DuCbwDU1YEuGl0P-viNKsuuip14EiQtAaGbIN-TwDULfhKRE5tzFae5tzL0jscyFjolhTtosM9bV-x3j-_T2gX-fidkJEt1dmBC0b_T8qlwsr8r5rxBbuVqafhcn1p-MhylNWMJp_xSdZox1Lnoz_TKRS97wkDLw58GvB0xTn3_VGXNgvqawppGjRShw9f8LYP4dJ_nHwjN6iV60iBEPmpG9QieufI0uJg3l9NMlnh5uUG0u8QWeHMion96gzaCsd6tBtGs8ME2qCFx5PFIbo1Y1H0mJ1aOaA0rEd2D4eNi0HbrFAqvS4p9LBW_h86h-vjYh8xcUTXfLqu1xV0fRv0UPo5vp8DZuEy3Ehmd0G3vGiHaJ1ISqTCifZV651CoqLReWAQh3XhuTplQmlrmE-dQTaRKhCFE88ewdOiur0n1AWHjOJbWUpFJyo7QEWGwTbnKdJgbAWYS-dn--WDV8GgX4IbWoioOoInRdC2XfoubADgXV-rFoNaEw4ImmzHJPBeXaWU2s5jB155bnVkkbofNOpEVrmJsCVuo0B1BIRIS-7KvBpOpzElW6ahfaAJBKRCYj9L7RgP1IOg2KUHakG0dDPa4BLQ603a3Wfvzvnp_Qc4BrgY034efobLveuc8Aiba6B4Ywy3ro2fXN_eRHL2wswHPM814wjt8qKRJQ |
link.rule.ids | 230,315,733,786,790,870,891,2115,2236,12083,21416,24346,27955,27956,31752,31753,33777,33778,43343,43838,53825,53827,74100,74657 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Jb9NAFB5BeoALYq-hwCBQT7WY3Z4TSqNWAdIoglTqzRrPUiK1dshy6L_nje0kBCFu9izSyG_75s34ewh9lJoRnQufqjy4VARPUp3LMiWWe-2yzDof8x0XYzW8FF-v5FWXcFt21yo3PrFx1K62MUf-CVysyiGaE_l5_iuNVaPi6WpXQuM-OoiUm3kPHZyejSffN76Yy1yLlpSUw1TY5APAiYdhfC8MNWz9_4KYf9-U_CP0nD9GjzrMiPutkJ-ge756io4nLen03Qme7v6hWp7gYzzZ0VHfPUPLfhXz1SDcBe7btlgErgM-N0tr5pGRpMLm2swAJ-IRmD4etGMH_uYGm8rhH7cGnprXvf7Zwja1v6Bpur6tuxmjeI_-Obo8P5sOhmlXaiG1ImOrNHBOSk91SZjJpAlZFoxXzjDthHQcYLgPpbVKMU0d95QHFYi2VBpCjKCBv0C9qq78IcIyCKGZY0RpLawpNQBjR4XNS0UtwLMEfdh8-WLeMmoUsBOJ8il28knQaRTKdkRkwW4a6sV10RlVYWEvqrgTgUkmSu9K4koBzjt3IndGuwQdbURadKa5LHaKlKD3224wqnhSYipfr5sxAKWozHSCXrYasF0JxHwGuIgkKNvTjb2l7vdUs58NcbdilFPBXv1_We_Qg-H0YlSMvoy_vUYPAaE1BLxUHKHearH2bwAFrcq3nar_Bh2rCYw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgSIgXxDdhA4xAe1o0fyd-QqVQDShTJTqpb5Hjj1FpS7qmfdh_zzlJW4oQb4ntRFbufPc7-_I7hD5IzYjOhU9VHlwqgiepzmWZEsu9dllmnY_7HT_O1dmF-DaTsz7_qenTKjc2sTXUrrZxj_wUTKzKwZsTeRr6tIjJ59HHxU0aK0jFk9a-nMZddA-8JIllHLLZNvjiMteioyfl8BII9wHqxGMxvueQWt7-f4HNv3Mm_3BCo0foYY8e8aAT92N0x1dP0PGko5--PcHT3d9UzQk-xpMdMfXtU9QMqrhzDWJe4oHtykbgOuCRaaxZRG6SCptLMwfEiMdgBPCwGzv0V1fYVA7_vDZw1d7u9c-Xtq0CBk3T9XXdPzGOGfXP0MXoy3R4lvZFF1IrMrZKA-ek9FSXhJlMmpBlwXjlDNNOSMcBkPtQWqsU09RxT3lQgWhLpSHECBr4c3RQ1ZV_ibAMQmjmGFFaC2tKDRDZUWHzUlELQC1B7zdfvlh03BoFxCRRPsVOPgn6FIWyHRH5sNuGenlZ9MursBCVKu5EYJKJ0ruSuFKAGc-dyJ3RLkFHG5EW_SJtip1KJejdthuWVzwzMZWv1-0YAFVUZjpBLzoN2M4EvD8DhEQSlO3pxt5U93uq-a-Wwlsxyqlgr_4_rbfoPuh4Mf56_v0QPQCo1jLxUnGEDlbLtX8NcGhVvmn1_De7GQxJ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Anticancer+Activity+of+Fascaplysin+against+Lung+Cancer+Cell+and+Small+Cell+Lung+Cancer+Circulating+Tumor+Cell+Lines&rft.jtitle=Marine+drugs&rft.au=Rath%2C+Barbara&rft.au=Hochmair%2C+Maximilian&rft.au=Plangger%2C+Adelina&rft.au=Hamilton%2C+Gerhard&rft.date=2018-10-14&rft.issn=1660-3397&rft.eissn=1660-3397&rft.volume=16&rft.issue=10&rft.spage=383&rft_id=info:doi/10.3390%2Fmd16100383&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_md16100383 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1660-3397&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1660-3397&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1660-3397&client=summon |